Curanex Pharmaceuticals Inc
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities
Item 2. Unregistered Sales Of Equity Securities And Use Of Proceeds
Except as stated below, there were no sales of equity securities during the period covered by this Quarterly Report that were not registered under the Securities Act and were not previously reported in a Current Report on Form 8-K filed by the Company.
On March 18, 2026, we issued 24,000 shares of Common Stock to our Chief Scientific Officer and director as compensation for services provided to the Company.
The above issuance did not involve any underwriters, underwriting discounts or commissions or any public offering and we believe is exempt from the registration requirements of the Securities Act by virtue of Section 4(2) thereof as transactions not involving a public offering.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.